Summit Therapeutics Inc. (SMMT) Current Ratio
- Current ratio · latest quarter: Value 6.96×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.96× | Current assets / current liabilities. $720.58M ÷ $103.57M ≈ 6.96× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 720.58M USD | Assets, Current |
| Current obligations | 103.57M USD | Liabilities, Current |
| Cash and equivalents | 419.37M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 22.90M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $720.58M | $103.57M | $419.37M | (m) | (m) | (m) | $22.90M | (m) | 6.96× |
| 2026-03-31 | $616.60M | $83.27M | $106.52M | (m) | (m) | (m) | $27.55M | (m) | 7.41× |
| 2025-12-31 | $720.30M | $72.99M | $225.27M | (m) | (m) | (m) | $20.29M | (m) | 9.87× |
| 2025-09-30 | $246.47M | $64.93M | $238.55M | (m) | (m) | (m) | $22.25M | (m) | 3.80× |
| 2025-06-30 | $309.24M | $60.33M | $297.87M | (m) | (m) | (m) | $22.98M | (m) | 5.13× |
| 2025-03-31 | $370.75M | $34.88M | $211.53M | (m) | (m) | (m) | $4.99M | (m) | 10.63× |
| 2024-12-31 | $423.75M | $41.73M | $104.86M | (m) | (m) | (m) | $4.64M | (m) | 10.15× |
| 2024-09-30 | $490.29M | $59.01M | $93.78M | (m) | (m) | (m) | $3.25M | (m) | 8.31× |
| 2024-06-30 | $328.79M | $140.17M | $28.43M | (m) | (m) | (m) | $3.34M | (m) | 2.35× |
| 2024-03-31 | $163.26M | $23.44M | $61.29M | (m) | (m) | (m) | $6.37M | (m) | 6.97× |
| 2023-12-31 | $189.71M | $20.41M | $71.42M | (m) | (m) | (m) | $2.67M | (m) | 9.30× |
| 2023-09-30 | $204.95M | $113.74M | $23.79M | (m) | $0.00 | (m) | $3.31M | (m) | 1.80× |
| 2023-06-30 | $227.50M | $11.93M | $42.12M | (m) | $0.00 | (m) | $987.00K | (m) | 19.07× |
| 2023-03-31 | $248.03M | $17.44M | $70.97M | (m) | $0.00 | (m) | $710.00K | (m) | 14.22× |
| 2022-12-31 | $656.71M | $38.78M | $348.61M | (m) | $349.00K | (m) | $355.00K | (m) | 16.93× |
| 2022-09-30 | $137.12M | $16.68M | $121.97M | (m) | $140.00K | (m) | $1.43M | (m) | 8.22× |
| 2022-06-30 | $79.40M | $15.17M | (m) | (m) | $238.00K | (m) | $3.57M | (m) | 5.23× |
| 2022-03-31 | $99.44M | $22.72M | (m) | (m) | $870.00K | (m) | $6.96M | (m) | 4.38× |
| 2021-12-31 | $97.31M | $25.62M | $71.79M | (m) | $1.46M | (m) | $4.37M | (m) | 3.80× |
| 2021-09-30 | $102.21M | $22.79M | (m) | (m) | $2.29M | (m) | $5.88M | (m) | 4.49× |
| 2021-06-30 | $121.48M | $21.89M | $103.39M | (m) | $1.05M | (m) | $6.95M | (m) | 5.55× |
| 2021-03-31 | $125.22M | $73.05M | $102.19M | (m) | $447.00K | (m) | $4.11M | (m) | 1.71× |
| 2020-12-31 | $87.67M | $19.89M | (m) | (m) | $331.00K | (m) | $6.14M | (m) | 4.41× |
| 2020-09-30 | $42.08M | $14.74M | $21.27M | (m) | $4.08M | (m) | $2.49M | (m) | 2.85× |
| 2020-06-30 | $55.55M | $13.20M | $36.41M | (m) | $464.00K | (m) | $3.09M | (m) | 4.21× |
| 2019-12-31 | $79.63M | $13.77M | $63.84M | (m) | $541.00K | (m) | $4.47M | (m) | 5.78× |
| 2019-01-31 | $61.25M | $17.18M | $35.24M | (m) | $6.12M | (m) | $5.80M | (m) | 3.56× |
| 2018-01-31 | $50.81M | $32.58M | $28.50M | (m) | $3.90M | (m) | $6.26M | (m) | 1.56× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |